Author(s): Manikanth Reddy Yarala, Sowjanya Gummadi


DOI: 10.52711/0974-360X.2024.00296   

Address: Manikanth Reddy Yarala, Sowjanya Gummadi*
Department of Pharmaceutical Analysis, GITAM School of Pharmacy,
GITAM (Deemed to be University), Visakhapatnam-530045, Andhra Pradesh.
*Corresponding Author

Published In:   Volume - 17,      Issue - 4,     Year - 2024

This study presents a novel, sensitive and highly reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodology for the determination of N-Nitroso Safinamide, a genotoxic impurity in Safinamide mesylate. The optimized chromatographic conditions utilized Poroshell HPH-C18 (150 x 4.6 mm, 2.7 µm) and Ghost Buster columns with a flow rate of 0.8 ml/min and a column temperature of 40 °C. The mobile phase consisted of formic acid and methanol. Mass spectrophotometric analysis employed the Agilent Jet Stream Electrospray Ionization (AJS ESI) mode with a capillary voltage of 3500 V and a nitrogen gas flow rate of 12 L/min at 350 °C, while Multiple Reaction Monitoring (MRM) mode was used for scanning. Rigorous validation demonstrated the method's reliability and robustness. Linearity experiments showed a strong correlation coefficient of 0.999 between analyte concentration and peak area response. The method exhibited low limits of detection (LOD) and quantification (LOQ) of 0.00593 ppm and 0.01797 ppm, respectively, enabling accurate detection and quantification of N-Nitroso Safinamide at low concentrations. Precision studies demonstrated good repeatability and reproducibility, with % RSD values falling within acceptable limits. Specificity evaluations confirmed the absence of interferences in blank, standard, sample, and spiked sample solutions. The method's accuracy was established through satisfactory recovery values, ranging between 70 % and 130 % in spiked samples. The developed LC-MS/MS methodology offers a highly reliable and precise approach for quantifying N-Nitroso Safinamide in Safinamide mesylate.

Cite this article:
Manikanth Reddy Yarala, Sowjanya Gummadi. Trace level Quantification of N-Nitroso Safinamide: A Genotoxic Impurity in Safinamide Mesylate Using ESI-MS/MS. Research Journal of Pharmacy and Technology.2024; 17(4):1867-3. doi: 10.52711/0974-360X.2024.00296

Manikanth Reddy Yarala, Sowjanya Gummadi. Trace level Quantification of N-Nitroso Safinamide: A Genotoxic Impurity in Safinamide Mesylate Using ESI-MS/MS. Research Journal of Pharmacy and Technology.2024; 17(4):1867-3. doi: 10.52711/0974-360X.2024.00296   Available on:

1.    Lew M. Overview of Parkinson’s disease. Pharmacotherapy. 2007; 27(12): 155S-160S.
2.    Thobois S, Delamarre-Damier F, Derkinderen P. Treatment of motor dysfunction in Parkinson’s disease: an overview. Clinical Neurology and Neurosurgery. 2005; 107(4): 269-281.
3.    Nagatsu T, Sawada M. L-dopa therapy for Parkinson’s disease: Past, present, and future. Parkinsonism and Related Disorders. 2009; 15: S3-S8.
4.    Perez-Lloret S, Rascol O. The safety and efficacy of Safinamide mesylate for the treatment of Parkinson’s disease. Expert Review of Neurotherapeutics. 2016; 16(3): 245–58.
5.    Schneider A, Sari AT, Alhaddad H, Sari Y. Overview of therapeutic drugs and methods for the treatment of parkinson’s disease. CNS and Neurological Disorders - Drug Targets. 2020; 19(3): 195–206.
6.    Yahr MD. Overview of present-day treatment of parkinson’s disease. Journal of Neural Transmission. 1978; 43(3): 227–38.
7.    Reddi A, Mujahid M, Sasikumar M, Muthukrishnan M. A new enantioselective synthesis of the anti-parkinson agent Safinamide. Synthesis. 2014; 46(13): 1751-1756.
8.    Malek N, Grosset D. Investigational agents in the treatment of parkinson’s disease: focus on Safinamide. Journal of Experimental Pharmacology. 2012; 5(4): 85-90.
9.    Zou L, Sun L, Zhang H, Hui W, Zou Q, Zhu Z. Identification, characterization, and quantification of impurities of Safinamide mesilate: Process-Related Impurities and Degradation Products. Journal of AOAC International. 2017; 100(4): 1029–37.
10.    Adhao VS, Thenge RR, Sharma J, Thakare M. Development and validation of stability indicating RP-HPLC method for determination of Safinamide mesylate. Jordan Journal of Pharmaceutical Sciences. 2020; 13(2): 149-159.
11.    Baviskar PC, Bachhav RS. An overview on various analytical methods for estimation of Safinamide from its bulk and pharmaceutical dosage form. World Journal of Pharmaceutical Sciences. 2021; 9(11): 114–119.
12.    Amrutkar GR, Aher SS, Bachhav RS. Stability indicating RP-HPLC method development and validation for estimation of Safinamide in bulk drug and dosage form. International Journal of Pharmacy and Biological Sciences. 2022; 12(4): 2321–3272.
13.    Redasani VK, Mali BJ, Surana SJ. Development and validation of HPTLC method for estimation of Safinamide mesylate in bulk and in tablet dosage form. ISRN Analytical Chemistry. 2012; 2012: 1–4.
14.    Rehman A, Nath T, Pasupati T, Harsha K, Sreedhar C. Method for determination of Safinamide mesylate in bulk and tablet dosage form by both RP-HPLC AND HPTLC. Journal of Emerging Technologies and Innovative Research. 2021; 8(8): a421–31.
15.    Mohan RT, Balasekhara RC, Srinivasa BP. Application of liquid chromatography with tandem mass spectrometric method for quantification of Safinamide in invitro samples. International Journal of Life Science and Pharma Research. 2020; 10(2): 55–61.
16.    El-Sayed HM, Abdellatef HE, Hendawy HAM, El-Abassy OM, Ibrahim H. DoE-enhanced development and validation of eco-friendly RP-HPLC method for analysis of Safinamide and its precursor impurity: QbD approach. Microchemical Journal. 2023; 190:108730.
17.    Step. Committee for Medicinal Products for Human Use, ICH guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk-questions and answers. [cited 2023 Jul 2];
Available from:

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available